Buyout hits you're looking 3-8$ is what people say around here. However CIAB has LONG term applications that are applicable not only to pancreatic cancer, but also to diabetes, and all types of cancers.
Platform technology. This is my own personal belief, that PMCB will go as far 10-15$.
Beyond that it's likely to hit 40$. Pharmacyte's mission, according to Waggner, is to be a HOUSEHOLD NAME.
Think about that for a second. Household names don't trade for 5-10$ a share.
I believe they can make it happen. They've got the technology, enthusiasm, qualifications, product, applications, funding, market, innovation, and the vision to make it happen.
It's the right time and place.
News 
Market Data 
Discover 
